Results 271 to 280 of about 2,934,766 (329)

Emerging Neuroprotective Strategies: Unraveling the Potential of HDAC Inhibitors in Traumatic Brain Injury Management. [PDF]

Curr Neuropharmacol
Ye L, Li W, Tang X, Xu T, Wang G.
europepmc   +1 more source

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization. [PDF]

ACS Chem Biol
Bauer N, Balourdas DI, Schneider JR, Zhang X, Berger LM, Berger BT, Schwalm MP, Klopp NA, Siveke JT, Knapp S, Joerger AC.   +10 more
europepmc   +1 more source

Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page 174-184, February 2026.
This EBMT Practice Harmonisation and Guidelines Committee consensus provides practical recommendations for the selection, timing and conduct of allogeneic transplantation in advanced‐stage mycosis fungoides and Sézary syndrome, aiming to optimize outcomes through early multidisciplinary collaboration and evidence‐based decision‐making.
Gandhi Damaj, Adèle de Masson, Peter Dreger, Ali Bazarbachi, Philipp Berning, Rafael F. Duarte, Christopher P. Fox, Emmanuella Guenova, Olivier Hermine, Charalampia Kyriakou, Alina Tanase, Olivier Tournilhac, Wojiech Jurczak, Imke E. Karsten, Stéphanie Nguyen Quoc, Yasmina Serroukh, Federico Stella, Gerald Wulf, Anna Sureda, Evangelia Papadavid, Pablo L. Ortiz‐Romero, Annalisa Ruggeri, Isabel Sánchez‐Ortega, Julia J. Scarisbrick, Ibrahim Yakoub‐Agha, Francesco Onida, Norbert Schmitz   +26 more
wiley   +1 more source

Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution

International Journal of Cancer, Volume 158, Issue 2, Page 314-332, 15 January 2026.
Abstract Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create
Kira Furlano, Tina Keshavarzian, Nadine Biernath, Annika Fendler, Maria de Santis, Joachim Weischenfeldt, Mathieu Lupien   +6 more
wiley   +1 more source

Underlying anti-cancer mechanisms of histone deacetylase (HDAC) inhibitors in tamoxifen-resistant breast cancer cells. [PDF]

Iran J Basic Med Sci
Wang L, Xu Y, Gao C.
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer. [PDF]

Int J Oncol
He Y, Ma Y, Zhu Y, Zhang J, Zhao S, Zhang D, Xu D, Li Y, Tong Z, Zhao W.   +9 more
europepmc   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

International Journal of Cancer, Volume 158, Issue 2, Page 423-432, 15 January 2026.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar, Lev M. Kats, Emily Gruber   +2 more
wiley   +1 more source

High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line. [PDF]

BMC Cancer
Wang S, Oliveira-Silveira J, Fang G, Kang J.   +3 more
europepmc   +1 more source